• head_banner_01

Tirzepatide

Short Description:

Tirzepatide is a novel dual agonist of GIP and GLP-1 receptors, developed for the treatment of type 2 diabetes and obesity. As a first-in-class “twincretin,” Tirzepatide enhances insulin secretion, suppresses glucagon release, and significantly reduces appetite and body weight. Our high-purity Tirzepatide API is chemically synthesized, free of host-cell-derived impurities, and meets international regulatory standards for quality, stability, and scalability.


Product Detail

Product Tags

Tirzepatide API
Tirzepatide is a groundbreaking synthetic peptide that functions as a dual agonist of both glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. It represents a new class of incretin-based therapies known as “twincretins”, offering enhanced metabolic control for patients with type 2 diabetes and obesity.

Our Tirzepatide API is produced through advanced chemical synthesis techniques, ensuring high purity, low impurity levels, and excellent batch-to-batch consistency. Unlike rDNA-derived peptides, our synthetic API is free from host cell proteins and DNA, significantly improving biosafety and regulatory compliance. The manufacturing process has been optimized for scale-up to meet growing global demand.

Mechanism of Action
Tirzepatide works by simultaneously stimulating both GIP and GLP-1 receptors, providing complementary and synergistic effects:

GIP receptor activation: enhances insulin secretion and may improve insulin sensitivity.

GLP-1 receptor activation: suppresses glucagon release, delays gastric emptying, and reduces appetite.

Combined activity leads to:

Improved glycemic control

Decreased body weight

Enhanced satiety and reduced food intake

Clinical Research & Outcomes
Tirzepatide has demonstrated unprecedented efficacy in multiple large-scale clinical trials (SURPASS & SURMOUNT series):

Superior HbA1c reduction compared to GLP-1 RAs (e.g., Semaglutide)

Weight loss up to 22.5% in obese patients — comparable to bariatric surgery in some cases

Rapid onset of effect and durable glycemic control over long-term use

Improved cardiometabolic markers: including blood pressure, lipids, and inflammation

Tirzepatide is not only reshaping the treatment paradigm for type 2 diabetes but also emerging as a major therapeutic option for medical weight loss and metabolic syndrome.

Quality & Compliance
Our Tirzepatide API:

Meets global quality standards (FDA, ICH, EU)

Tested via HPLC for low levels of known and unknown impurities

Manufactured under GMP conditions with full process documentation

Support large-scale production R&D


  • Previous:
  • Next:

  • Write your message here and send it to us